Magee Thomson Investment Partners’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Magee Thomson Investment Partners’s Portfolio LJPC Stock Details LJPC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$1K	Buy	+17	New	+$434	﹤0.01%	96

Other funds holding LJPC

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Magee Thomson Investment Partners's LJPC Position: Q1 2017 in Review

Magee Thomson Investment Partners opened a new position in La Jolla Pharmaceutical Company (LJPC) in Q1 2017: 17 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #96 among its holdings.

96 funds tracked by Wall St. Rank hold LJPC as of Q1 2017.

Magee Thomson Investment Partners held 17 shares of La Jolla Pharmaceutical Company worth $1K as of Q1 2017.
La Jolla Pharmaceutical Company was a new Magee Thomson Investment Partners position in Q1 2017.
La Jolla Pharmaceutical Company made up ﹤0.01% of Magee Thomson Investment Partners's portfolio in Q1 2017, its #96 holding.
96 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q1 2017.

Based on Magee Thomson Investment Partners's 13F filing for Q1 2017, filed 21 Apr 2017.